It wasn't a criticism of your post, I just don't think MNY with such a low share of the market has any real limitations on growing it's business except it's funding available. MNY already vets it's applicants heavily & hasn't had a problem growing.
There's the possibility that MNY future growth may well be restricted by it's inability to get further funding due to tight credit conditions. Credit tightening cuts both ways, not that it's an issue for this year.
- Forums
- ASX - By Stock
- SVR
- Ann: Dividend/Distribution - MNY
Ann: Dividend/Distribution - MNY, page-24
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
-0.025(1.87%) |
Mkt cap ! $269.3M |
Open | High | Low | Value | Volume |
$1.35 | $1.35 | $1.30 | $16.06K | 12.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 374 | $1.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 2130 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 332 | 1.305 |
2 | 236 | 1.295 |
2 | 6149 | 1.285 |
1 | 2350 | 1.280 |
1 | 2350 | 1.275 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 2130 | 7 |
1.315 | 8367 | 8 |
1.320 | 3172 | 3 |
1.325 | 7662 | 2 |
1.330 | 1326 | 3 |
Last trade - 14.17pm 13/11/2024 (20 minute delay) ? |
Featured News
SVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online